Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Comprehensive Review of Early and Late Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatments for Hematologic Malignancies
Ayrton Bangolo, Behzad Amoozgar, Charlene Mansour, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 282-282
Open Access | Times Cited: 1
Bispecific Aptamer-Drug Conjugates Selectively Eliminate Malignant Hematologic Cells for Treating Acute Myeloid Leukemia
Xiaodong Li, Jiacheng Dai, Yuanyuan Shi, et al.
Langmuir (2025)
Closed Access | Times Cited: 1
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
Zhengdong Ai, Bing Wang, Yunlong Song, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon
Keiji Sugiyama, Ian Chau
Cancer Treatment Reviews (2025) Vol. 133, pp. 102888-102888
Open Access
Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy
R R Zhao, Xing-Xing Fan
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1440-1440
Open Access
Quantifying antibody binding: techniques and therapeutic implications
James Lodge, Lewis Kajtar, R. E. Duxbury, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access
Dual‐Targeted Protein MRI Contrast Agent for Early Detection of Micrometastases
Rongtao Hu, Zhiyang Wang, Tinghui Shen, et al.
Aggregate (2025)
Open Access
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database
Xiangyang Le, Yefu Zhang, Junlong Ma
Expert Opinion on Drug Safety (2025)
Closed Access
Integration of QSAR Models with High Throughput Screening to Accelerate the Development of Polishing Chromatography Unit Operations
Michael Hartmann, Michael Rauscher, Julie Robinson, et al.
Journal of Chromatography A (2025) Vol. 1747, pp. 465818-465818
Closed Access
Development and validation of an LC–MS/MS method for pharmacokinetic assessment of a bispecific antibody (YBSW015) targeting SARS-CoV-2
Yuanyuan Chai, Ling Zhou, Yan Yang, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025) Vol. 260, pp. 116770-116770
Closed Access
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system
Xiang Fu, Dongqiang Zeng, Min Li, et al.
Expert Opinion on Drug Safety (2025), pp. 1-9
Closed Access
Lanthanide-bimetallic organic frameworks: from mechanism and sensors design to ratiometric fluorescent applications
Jialing Zhou, Xiao Hu, Chen Liu, et al.
Coordination Chemistry Reviews (2025) Vol. 534, pp. 216574-216574
Closed Access
Emerging cell therapies in the vasculitis field
Meghan E. Free
Lara D. Veeken (2025) Vol. 64, Iss. Supplement_1, pp. i11-i14
Closed Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
Yan Zhang, Xinyu Liu, Shengxiang Ren
Expert Opinion on Biological Therapy (2025)
Closed Access
Characteristics of second primary malignancies following bispecific antibodies therapy
Xiaojie Liang, Baiwei Luo, B.Y. Lin, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e011200-e011200
Open Access
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
Lorenzo Guidi, Julian Etessami, Carmine Valenza, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Immunotherapy in chronic lymphocytic leukemia: advances and challenges
Pan Gao, Yang Zhang, Jun Ma, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
The diversity of CD8+ T cell dysfunction in cancer and viral infection
Lorenzo Galluzzi, Kellie N. Smith, Adrian Liston, et al.
Nature reviews. Immunology (2025)
Closed Access
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance
Sabarish Ayyappan, Jeremy T. Larsen, James F. Sanchez, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Modular Design of T Cell Nanoengagers for Tumor Immunotherapy via Genetically Engineered Lipid‐Tagged Antibody Fragments
Helong Kang, Yuanke Li, Fude Sun, et al.
Advanced Materials (2025)
Closed Access
Bispecific antibodies combined with chemotherapy in solid tumor treatment, the path forward?
Yici Yan, Jing Yuan, Yanyang Peng, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Advancements in Ocular Therapy: A Review of Emerging Drug Delivery Approaches and Pharmaceutical Technologies
Bhupendra Raj Giri, Deeksha Jakka, Michael A. Sandoval, et al.
Pharmaceutics (2024) Vol. 16, Iss. 10, pp. 1325-1325
Open Access | Times Cited: 3
Molecular imaging supports the development of multispecific cancer antibodies
C. Winkel, Frank R. Pierik, Adrienne H. Brouwers, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 12, pp. 852-866
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top